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We compared real-time LightCycler and TaqMan assays and the GP5/6 PCR/enzyme immunoassay
(EIA) to assess the human papillomavirus type 16 (HPV16) load in cervical scrape specimens. Both real-time
PCR assays determined the HPV16 load in scrape specimens similarly. The level of agreement between these
assays and the GP5/6 PCR/EIA was low (P  0.004), suggesting that the latter method is not suited for
quantifying HPV16 DNA.
It is now well established that a persistent infection with a
high-risk human papillomavirus (hr-HPV) type is a necessary
cause of cervical cancer (1, 7, 14). In addition, several studies
have shown that an increased human papillomavirus (HPV)
DNA load within a cervical smear specimen is associated with
an increased risk of cervical intraepithelial neoplasia grade 3
(CIN3) and cervical carcinomas (3, 6, 11, 13). Therefore, viral
load assessments as follow-ups of consensus hr-HPV tests may
have implications for the identification of women among those
with hr-HPV infections that have the highest risk of CIN3
lesions or cervical carcinomas (10). However, data on the pos-
sible clinical value of viral load are not consistent, which in part
may reflect the use of different quantification assays (4, 8, 9).
Here, we compared a newly developed real-time PCR assay
based on fluorescence resonance energy transfer (LightCycler;
see Table 1) with a previously described real-time PCR assay
based on fluorigenic 5 nuclease chemistry (TaqMan) (13) and
the semiquantitative consensus HPV GP5/6 PCR enzyme
immunoassay (EIA) (12) for their abilities to assess the HPV16
load in cervical scrapings as a follow-up of GP5/6 PCR
typing. To that end, a total of 109 cervical scrapings were
randomly selected from a population-based screening study
among scrape specimens that were HPV16 positive by
GP5/6 PCR genotyping (12). These comprised 54 samples
classified as normal and 55 classified as borderline or mild
dyskaryosis (BMD). BMD equals atypical squamous cells
(ASC) of undetermined significance/ASC–high-grade squa-
mous intraepithelial lesion/ASC–low-grade squamous intraepi-
thelial lesion, according to the Bethesda 2001 classification (2).
The scrape specimens comprised 80 cases with single infections
and 29 cases with multiple infections including HPV16. Thir-
teen randomly chosen GP5/6 PCR-negative cervical scrap-
ings were also subjected to real-time PCR assays.
Real-time PCR was performed on 100 ng target DNA using
reagents the same as those described by Stevens et al. (10),
except that 3.5 mM MgCl2 was used for HPV16. Details of
primers, probes, and cycling determinants are given in Table 1.
For HPV16 quantification, standard curves of 10-fold dilutions
of pHPV16 plasmid DNA (ranging from 10 to 105 fg) spiked in
100 ng human placental DNA were used, whereas those of the
-globin gene contained only human placental DNA (ranging
from 3 pg to 30 ng). Samples were tested in duplicate, and the
values obtained were averaged. The real-time PCR assays de-
termined the HPV16 load normalized per cell and per scrape
specimen, whereas the GP5/6 PCR/EIA assayed the load
per scrape specimen expressed as EIA optical density (OD)
values after a 1-hour substrate incubation (5).
The median HPV16 loads per cell of the 109 cervical sam-
ples determined by the LightCycler and TaqMan assays were
4.0 copies/cell (range, 0.0 to 137.4) and 6.7 copies/cell (range,
0.0 to 346.2), respectively. The HPV16 copies/cell values mea-
sured by TaqMan were on average 1.6 times higher (95%
confidence interval [CI], 1.3 to 2.1) than those measured by
LightCycler. The correlation between both assays for deter-
mining HPV16 copies/cell was strong (Spearman   0.84; Fig.
1A) and their agreements were moderate (kappa value calcu-
lated after categorization of the variables in tertiles, 0.59).
Correlation and agreement were not significantly influenced by
the level of dyskaryosis (normal cytology or BMD) or the
number of HPV types present in a scrape specimen. None of
the 13 GP5/6 PCR-negative cervical scrape specimens re-
vealed any HPV16 signal in both LightCycler and TaqMan
assays, whereas all revealed -globin gene PCR signals with
both assays within the same range as that of the GP5/6
PCR-positive scrapings.
Subsequently, the semiquantitative GP5/6 PCR/EIA was
used to determine the HPV16 load per cervical scrape speci-
men. The median EIA OD value of the GP5/6 PCR after
1-hour substrate incubation was 1.17 (range, 0.07 to 1.67). The
median numbers of calculated HPV16 copies/scrape specimen
were 5.1  106 (range, 3.3  104 to 2.5 109) and 8.1  106
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(range, 8.0  104 to 4.0  109) by LightCycler and TaqMan,
respectively. The TaqMan assay determined the number of
HPV16 copies/scrape specimen to be on average 1.7 times
(95% CI, 1.3 to 2.2) higher than the LightCycler assay did.
Conversely, the median amount of cells per scrape specimen
as calculated by both techniques did not differ (mean of
-globin ratios, 1.00; 95% CI, 1.00 to 1.01). Correlation and
agreement were strong (Spearman   0.87) and good
(kappa value  0.64), respectively, between the two real-
time PCR assays in determining the HPV16 load/scrape
specimen (Fig. 1B). These values decreased when compar-
ing either of the two real-time PCR assays with the semi-
quantitative GP5/6 PCR/EIA (Fig. 1C and D). Correla-
tion coefficients were 0.81 and 0.77 and kappa values were
0.53 and 0.50 for GP5/6 PCR/EIA values versus Light-
Cycler and TaqMan values, respectively. The number of
HPV types present in a scrape specimen or the degree of
dyskaryosis did not significantly influence the correlations.
By means of a regression model for standardized values, we
tested for differential effects of TaqMan and GP5/6
PCR/EIA on LightCycler values and found a significantly
higher coherence between the results for the different real-
time PCR assays than between the results for GP5/6
PCR/EIA and the LightCycler assay (P  0.004).
The fact that TaqMan scored the HPV16 load overall higher
by a factor 1.6 to 1.7 than the LightCycler assay did could be
due to many factors. However, variables such as HPV16 primer
composition and the use of nonlinearized plasmids in the stan-
dard curve are most likely to be the underlying cause. Never-
theless, this difference was consistent throughout the whole
detection range, making data obtained with these two methods
still comparable when using a correction factor. Moreover,
data collected so far support the concept that there exist dif-
ferences in viral load values of several magnitudes between
clinically relevant and irrelevant HPV infections (10, 13).
Therefore, it is unlikely that a factor difference of 1.6 to 1.7 in
HPV16 load measured by the two real-time assays would be of
clinical relevance.
It should be realized that this comparative analysis was per-
formed on a random, cross-sectional series of smear specimens
with normal cytology or BMD. As a high viral load may be an
important determinant of CIN3 lesions or cervical carcinomas
(reviewed in reference 9), the choice of these samples could
potentially have led to studying a range of viral copy numbers
that fall beyond the level that would represent high-grade
cervical lesions. However, preliminary HPV16, -18, -31, and
-33 viral load analysis by LightCycler on cervical smear speci-
mens of women having underlying high-grade CIN lesions re-
vealed ranges of 9.2  104 to 5.3  108, 7.6  104 to 5.1  108,
2.4  104 to 9.4  108, and 2.0  106 to 8.5  108, respectively
(C. J. Hogenwoning et al., unpublished results). These ranges
correspond to the range of HPV16 copies/scrape specimen
found by the LightCycler assay (i.e., 3.3  104 to 2.5  109)
analyzed in this comparative study on smear specimens from
women with as-yet-unknown clinical outcomes.
In summary, we demonstrated that the TaqMan and the
LightCycler real-time PCR technologies produce similar re-
sults for the quantification of HPV16 DNA in cervical
scrape specimens and that both are therefore useful in the
detection of viral load in clinically relevant HPV infections.
However, the GP5/6 PCR/EIA assay was not adequate
for a precise assessment of the HPV load. Our data can be
of value for future comparisons of studies involving viral
TABLE 1. Primers, probes, and PCR specifications for the quantification of HPV16 and -globin targets
Assay (length of PCR
amplicon [bp]) Sequence (5 3 3)
a Position in
genomeb
Cycling
conditionsc
LightCycler HPV16 (158) fw: GAGGAGGAGGATGAAATAGATGGT 658–681 den: 95°C/3 s
re: GCCCATTAACAGGTCTTCCAA 816–796 ann: 56°C/15 s
dp: ACAAAAGGTTACAATATTGTAATGGGCTCT 735–706 elon: 72°C/9 s
ap: CCGGTTCTGCTTGTCCAGCTGG 703–682
LightCycler -globin (196) fw: GAGCCATCTATTGCTTACATTTGC 62122–62145 den: 95°C/3 s
re: TTGGTCTCCTTAAACCTGTCTTGT 62318–62295 ann: 55°C/15 s
dp: CCAGGGCCTCACCACCAACTTC 62275–62254 elon: 72°C/10 s
ap: CCACGTTCACCTTGCCCCACAG 62251–62230
TaqMan HPV16 (139) fw: CAGATACACAGCGGCTGGTTT 5914–5934 13
re: TGCATTTGCTGCATAAGCACTA 6053–6032
Probe: TGACCACGACCTACCTCAACACCTACACAGG 5936–5966
TaqMan -globin (152) fw: GAGCCATCTATTGCTTACATTTGC 403–426 13
re: TTGGTCTCCTTAAACCTGTCTTGT 555–532
Probe: TCTACCCTTGGACCCAGAGGTTCTTTGAGT 471–501
GP5/6 PCR (141) fw: TTTGTTACTGTGGTAGATACTAC 6624–6646 12
re: CTTTTTATTGACATTTAGTATAAG 6741–6764
Probe: GTCATTATGTGCTGCCATATCTACTTCAGA 6662–6691
a fw, forward primer; re, reverse primer; dp, donor probe (3 end labeled with fluorescein); ap, acceptor probe (3 end phosphorylated, HPV16 5 end labeled with
LightCycler-Red-640 and -globin 5 end labeled with LightCycler-Red-705). TaqMan probes are at the 5 end 6-carboxyfluorescein and at the 3 end 6-carboxytet-
ramethylrhodamine labeled; the EIA probe was 5 end digoxigenin labeled.
b GenBank accession numbers for HPV16 and -globin are K02718 and U01317, respectively.
c den, denaturation temperature and time; ann, annealing temperature and time; elon, elongation temperature and time. Cycling conditions for the final three assays
were as described previously by van Duin et al. (13) or by van den Brule et al. (12), as indicated.
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load assessment in relation to the risk of CIN3 lesions or
cervical carcinomas. In our setting, one such study is cur-
rently in progress.
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